Delivery Order SPE2DB22D2007-SPE2DB25FJ4UP
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $10,226.69. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) valued at $3,348.66 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to be fulfilled at the vendor's Conshohocken, Pennsylvania facility. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- The Defense Logistics Agency awarded a delivery order valued at $43,416.77 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract reflects no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, aligning with AmerisourceBergen's corporate headquarters location. This delivery order is issued under...
- On July 29, 2025, the Defense Logistics Agency awarded a delivery order valued at $7,172.24 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units). This firm fixed price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award supporting federal medical procurement. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,827.40 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of CAPLYTA 42 MG capsules (30-count units). The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award to this established pharmaceutical distributor. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location, with completion scheduled for September 9, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,244.42 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,236.39 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. CAPLYTA is a pharmaceutical treatment for psychiatric conditions, reflecting the company's...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $13,672.67. The delivery order, which serves as a child contract to a larger vehicle, is set to be completed by July 28, 2025. This award was competitively procured with no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Caplyta 10.5 mg capsules (30-count units) under a firm fixed price contract valued at $5,001.58. The contract, which is a non-set-aside competitive award, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order represents a single transaction within AmerisourceBergen's...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4UPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) with a ceiling value of $9,165.94. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 10, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to military and veteran healthcare systems. The company's extensive IDC enables flexible pharmaceutical support across multiple therapeutic domains, including specialty medications and brand-name drugs like CAPLYTA, which is used for psychiatric treatment, supporting the healthcare requirements of the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 9/9/25 |